Sanofi is to expand its vaccines manufacturing and build a new research center in its home market of France, as its CEO Paul Hudson looks to move on from a row over its COVID-19 vaccine candidate.
After Vaccines Row, Sanofi Invests In France, Macron To Secure Supplies
CEO Restates Commitment To France
Sanofi’s €610m investment helps row to be forgotten – though Macron will ‘place bets’ on several COVID-19 vaccines, not just France’s homegrown candidate.
More from Business
More from Scrip
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.